Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes

1 Aug 2024

Abstract excerpt

PURPOSE Patients with metastatic or advanced non–small cell lung cancer (NSCLC) need biomarker testing, including, in most cases, anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and PD-L1, to identify options for targeted therapies and to optimally incorporate immune checkpoint inhibitors into therapeutic regimens. We sought to examine real-world patterns of biomarker testing, quantify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39208373
DOI: 10.1200/po.24.00039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical OutcomesPMID 39208373Read ↗

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.Semantic proximity Read ↗

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.Semantic proximity Read ↗

Impact of Molecular Biomarker Test Availability and Timing on Metastatic Non-Small-Cell Lung Cancer Treatment Selection and Clinical Outcomes in the U.S. Medicare PopulationSemantic proximity Read ↗

Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study.Semantic proximity Read ↗

Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.Semantic proximity Read ↗

Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.Semantic proximity Read ↗

Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Barries in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World-Evidence ScenarioSemantic proximity Read ↗

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).Semantic proximity Read ↗

Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.Semantic proximity Read ↗

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.